Skip to content
  • About
    • Supporter
    • Expert Index
    • Editorial Board
    • Editorial Team
    • Editorial Policy
  • Contact
  • Sign up

Visit

vjhemonc logo
VJRegenMed
Logo
  • Home (current)
  • Specialties
    Hematology
    Oncology
    Musculoskeletal Disorder
    Rare Disease
    Metabolic Disorder
    Cardiovascular Disease
    Ophthalmology
    Neurology
    Infectious Disease
    View all Specialties
  • Technologies
    Cell Therapy
    MSC
    iPSC
    Gene Therapy
    Genome Editing
    Extracellular Vesicles
    CAR-T Therapy
    TCR Therapy
    Tissue-Engineering & Biomaterials
    View all Technologies
  • Topics
    Treatment
    Immuno-Oncology
    Trial Updates
    Perspectives
    Manufacturing
    COVID-19
    View all Topics
  • Conferences
    ASH 2022
    TCT 2022
    Meeting on the Med 2022
    ICLE 2022
    Advanced Therapies Week 2022
    TERMIS 2021
    ESGCT 2021
    Meeting on the Mesa 2021
    Advanced Therapies 2021
    View all Conferences
    • About
      • Supporter
      • Expert Index
      • Editorial Board
      • Editorial Team
      • Editorial Policy
    • Contact
    • Sign up

Diabetes Mellitus

The role of regenerative medicine in treating diabetes 3:22
The role of regenerative medicine in treating diabetes
Lorenzo Piemonti • 11 Nov 2021
The future of regenerative medicine in transplantation 4:31
The future of regenerative medicine in transplantation
Giuseppe Orlando • 11 Nov 2021
Bio-engineering vascularized islet organs for T1D 4:36
Bio-engineering vascularized islet organs for T1D
Lorenzo Piemonti • 11 Nov 2021
Challenges in β cell replacement therapy 3:34
Challenges in β cell replacement therapy
Lorenzo Piemonti • 11 Nov 2021
Advanced cell selection for the manufacture of ProTrans cell therapy 2:34
Advanced cell selection for the manufacture of ProTrans cell therapy
Mathias Svahn • 6 Oct 2021
MSCs for type I diabetes 1:20
MSCs for type I diabetes
Lindsay Davies • 7 Jun 2021
ProTrans: Wharton’s jelly-derived MSC therapy for type I diabetes 2:13
ProTrans: Wharton’s jelly-derived MSC therapy for type I diabetes
Lindsay Davies • 7 Jun 2021
Developing the bioartificial pancreas 5:13
Developing the bioartificial pancreas
Ekaterine Berishvili • 1 Jun 2021
Tackling remaining obstacles to cell therapy for type I diabetes 3:54
Tackling remaining obstacles to cell therapy for type I diabetes
Ekaterine Berishvili • 1 Jun 2021
The future of cell-based therapies for type 1 diabetes 2:52
The future of cell-based therapies for type 1 diabetes
Ekaterine Berishvili • 1 Jun 2021
Journal Pages
  • Specialties
  • Technologies
  • Topics
  • Conferences
Newsletter

Receive the latest news and videos from VJRegenMed via email

Sign up
Contact Us

Contact us for more information

mmp logo

Magdalen Centre
The Oxford Science Park
Oxford OX4 4GA, United Kingdom

VJRegenMed logo
The content of VJRegenMed is intended for healthcare professionals
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • Editorial Policy